Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 360149, 11 pages
http://dx.doi.org/10.1155/2013/360149
Research Article

ITIH4: A New Potential Biomarker of “Toxin Syndrome” in Coronary Heart Disease Patient Identified with Proteomic Method

1Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
2Beijing University of Chinese Medicine, Beijing 100029, China
3Wuxi Hospital of Traditional Chinese Medicine, Wuxi 214001, China
4China-Japan Friendship Hospital, Beijing 100029, China

Received 5 May 2013; Accepted 15 June 2013

Academic Editor: Myeong Soo Lee

Copyright © 2013 Hao Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Ferreira and A. J. Lopes, “Chinese medicine pattern differentiation and its implications for clinical practice,” Chinese Journal of Integrative Medicine, vol. 17, no. 11, pp. 818–823, 2011. View at Google Scholar · View at Scopus
  2. M. F. Mei, “A systematic analysis of the theory and practice of syndrome differentiation,” Chinese Journal of Integrative Medicine, vol. 17, no. 11, pp. 803–810, 2011. View at Google Scholar · View at Scopus
  3. O. Li and H. Xu, “The occurrence of cardiovascular events of coronary heart disease inpatients and study on chinese medicine syndrome distribution laws,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 32, no. 5, pp. 603–606, 2012. View at Google Scholar
  4. Z. Y. Gao, J. C. Zhang, H. Xu et al., “Analysis of relationships among syndrome, therapeutic treatment, and Chinese herbal medicine in patients with coronary artery disease based on complex networks,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 8, no. 3, pp. 238–243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Xu, D. Z. Shi, H. J. Yin, J. C. Zhang, and K. J. Chen, “Blood-stasis and toxin causing catastrophe hypothesis and acute cardiovascular events: proposal of the hypothesis and its clinical significance,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 10, pp. 934–938, 2008. View at Google Scholar · View at Scopus
  6. Z. Zhang, G. L. Yang, H. Y. Zhang, M. Chen, Y. Chen, and Z. B. Luo, “A hypothesis of atherosclerosis plaque from the surgical carbuncle theory,” Liaoning Journal of Traditional Chinese Medicine, vol. 35, no. 2, pp. 201–202, 2008. View at Google Scholar
  7. L. Wang, L. B. Wei, X. F. Liu, S. W. Ding, and M. Peng, “Toxin theory and acute coronary syndrome,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 3, no. 12, pp. 1080–1081, 2005. View at Google Scholar
  8. W. X. Du, C. Y. Liu, H. X. Zhang, M. Zhang, and H. W. Song, “Acute myocardial infarction and TCM theory,” Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease, vol. 4, no. 5, pp. 434–436, 2006. View at Google Scholar
  9. W. Wu and R. Peng, “Progress of heat & toxin pathogenesis in coronary heart disease,” Journal of New Chinese Medicine, vol. 39, no. 6, pp. 3–4, 2007. View at Google Scholar
  10. H. Duan, H. K. Zhang, J. J. Liu, W. J. Nie, Y. Ma, and Y. Q. Gao, “Effect of berberine on IL-6 of carotid artery after ballon injury in rabbits,” Journal of Medical Forum, vol. 27, no. 10, pp. 6–9, 2006. View at Google Scholar
  11. M. Wu and J. Wang, “Advance on study in anti-atherosclerosis mechanism of berberine,” China Journal of Chinese Materia Medica, vol. 33, no. 18, pp. 2013–2016, 2008. View at Google Scholar
  12. Z. Q. Lei, S. Y. Chen, and X. M. Gao, Traditional Chinese Pharmacology, Shanghai Science and Technology Press, 1st edition, 1995.
  13. S. W. He, R. H. Zhao, H. J. Wu, and A. H. Guo, “Effect of wild purslane on atherosclerosis formation in rabbit,” Chinese Journal of Preventive Medicine, vol. 31, no. 2, p. 91, 1997. View at Google Scholar
  14. H. B. Tan, “Study of gynostemma pentaphylla on atherosclerosis in rabbit,” Chinese Journal of Gerontology, vol. 27, no. 6, pp. 519–521, 2007. View at Google Scholar
  15. L. D. Xie, L. X. Chen, S. X. Wu, and B. Nie, “Overview of clinical and basic research of Simiao Yong’an decoction in the treatment of coronary heart disease,” Global Traditional Chinese Medicine, vol. 5, no. 8, pp. 629–633, 2012. View at Google Scholar
  16. N. Zhu, X. M. Cao, Y. X. Cai, Y. Wu, and B. B. Wang, “Effect of huanglian jiedu decoction on CRP and TNF-αin coronary heart disease,” Journal of Emergency in Traditional Chinese Medicine, vol. 21, no. 4, pp. 542–543, 2012. View at Google Scholar
  17. G. Q. Li, P. Huang, H. M. Cheng et al., “Effect of huanglian jiedu decoction on T cell expression regulated by CD4+ CD25+ in rats with atherosclerosis,” Guangdong Medical Journal, vol. 31, no. 3, pp. 329–331, 2010. View at Google Scholar
  18. Z. Y. Guo, P. Huang, and G. Q. Li, “Effect of huanglian jiedu decoction on the expression of MCP-1/CCR2 mRNA in atherosclerosis rats,” Traditional Chinese Drug Research and Clinical Pharmacology, vol. 21, no. 6, pp. 583–586, 2010. View at Google Scholar
  19. F. Zheng, M. X. Zhou, H. Xu, and K. J. Chen, “Effects of herbs with function of activating blood circulation and detoxication on serum infl ammatory markers and blood lipids in stable patients with coronary heart disease,” China Journal of Traditional Chinese Medicine and Pharmacy, vol. 24, no. 9, pp. 1153–11576, 2009. View at Google Scholar
  20. X. H. Lu and S. W. Ding, “Clinical effect and mechanism on treating unstable angina pectoris by huanglian jiedu capsule,” Journal of Shandong University of Traditional Chinese Medicine, vol. 29, no. 6, pp. 457–460, 2005. View at Google Scholar
  21. R. Yu, S. X. He, X. L. Ye, and X. C. Wang, “The effect of therapeutic method of blood-activating and detoxifying of TCM on serum level of sCD40L in the patients with acute coronary syndrome,” Journal of Emergency in Traditional Chinese Medicine, vol. 17, no. 11, pp. 1500–1501, 2008. View at Google Scholar
  22. R. Yu, X. S. Hu, S. X. He, X. L. Ye, and X. X. Zhang, “The effect of huoxuejiedu decoction on serum level of MMP-1,MMP-9,TIMP-1 in the patients with acute coronary syndrome,” Journal of Emergency in Traditional Chinese Medicine, vol. 17, no. 10, pp. 1337–1346, 2008. View at Google Scholar
  23. C. Wen, H. Xu, Q. F. Chen, P. Li, and X. Sheng, “Effects of herbs of activation blood on atherosclerotic plaque morphology in ApoE gene-deficient mice,” Chinese Journal of Pathophysiology, vol. 21, no. 5, pp. 864–867, 2005. View at Google Scholar
  24. C. Wen, H. Xu, Q. F. Huang, and K. J. Chen, “Effect of drugs for promoting blood circulation on blood lipids and inflammatory reaction of atherosclerotic plaques in ApoE gene deficiency mice,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 25, no. 4, pp. 345–349, 2005. View at Google Scholar · View at Scopus
  25. M. X. Zhou, H. Xu, K. J. Chen, L. Pan, C. Wen, and J. G. Liu, “Effects of some active ingredients of Chinese drugs for activating blood circulation and detoxicating on blood lipids and atherosclerotic plaque inflammatory reaction in ApoE-gene knockout mice,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 2, pp. 126–130, 2008. View at Google Scholar · View at Scopus
  26. M. X. Zhou, H. Xu, K. J. Chen, L. Pan, C. Wen, and Y. R. Guo, “Effects of several herbal extractives with the effect of promoting blood flow and detoxication on atherosclerotic plaque stability in aorta of apoE-gene knockout mice,” Chinese Journal of Pathophysiology, vol. 24, no. 11, pp. 2097–2102, 2008. View at Google Scholar
  27. J.-C. Zhang, K.-J. Chen, G.-J. Zheng et al., “Regulatory effect of Chinese herbal compound for detoxifying and activating blood circulation on expression of NF-kappaB and MMP-9 in aorta of apolipoprotein E gene knocked-out mice,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 21, no. 1, pp. 40–44, 2007. View at Google Scholar
  28. K.-J. Chen, D.-Z. Shi, H. Xu et al., “XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China,” Chinese Medical Journal, vol. 119, no. 1, pp. 6–13, 2006. View at Google Scholar · View at Scopus
  29. H. Xu, K. J. Chen, D. Z. Shi, X. C. Ma, S. Z. lv, and J. M. Mao, “Clinical study of Xiongshao capsule in preventing resterosis after coronary interventional treatment,” Chinese Journal of Integrative Medicine, vol. 8, no. 3, pp. 162–166, 2002. View at Google Scholar
  30. Q.-H. Shang, H. Xu, X.-Y. Lu, C. Wen, D.-Z. Shi, and K.-J. Chen, “A multi-center randomized double-blind placebo-controlled trial of Xiongshao capsule in preventing restenosis after percutaneous coronary intervention: a subgroup analysis of senile patients,” Chinese Journal of Integrative Medicine, vol. 17, no. 9, pp. 669–674, 2011. View at Google Scholar · View at Scopus
  31. H. Xu, D. Z. Shi, K. J. Chen et al., “Effect of Xiongshao capsule on vascular remodeling in porcine coronary balloon injury model,” Chinese Journal of Integrative Medicine, vol. 6, no. 4, pp. 278–282, 2000. View at Google Scholar
  32. L.-Z. Li, J.-G. Liu, L.-B. Ma et al., “Effect of Xiongshao capsule on lipid metabolism and platelet aggregation in experimental atherosclerosis rabbits,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 12, pp. 1100–1103, 2008. View at Google Scholar · View at Scopus
  33. D. W. Zhang, L. Zhang, J. G. Liu, C. L. Wang, D. Z. Shi, and K. J. Chen, “Effects of Xiongshao capsule combined with ischemic postconditioning on monocyte chemoattractant protein-1 and tumor necrosis factor-α in rat myocardium with ischemic reperfusion injury,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 30, no. 12, pp. 1279–1283, 2010. View at Google Scholar
  34. F. Q. Xu, H. Xu, J. G. Liu, and K. J. Chen, “Effects of Xiongshao capsule on the proliferation of vascular smooth muscle cells in rabbits with atherosclerosis,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 10, pp. 912–916, 2008. View at Google Scholar · View at Scopus
  35. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical NomenclatureS, “Nomenclature and criteria for diagnosis of ischemic heart disease,” Circulation, vol. 59, no. 3, pp. 607–609, 1979. View at Google Scholar · View at Scopus
  36. Chinese Society of Cardiology, “Guideline for diagnosis and treatment of patients with unstable angina and non- ST-segment elevation myocardial infarction,” Chinese Journal of Cardiology, vol. 35, no. 4, pp. 295–304, 2007. View at Google Scholar
  37. Subcommittee of Cardiovascular Diseases of China Society of Integrated Traditional Chinese and Western Medicine, “Criteria for TCM syndrome differentiation of patients with coronary heart disease,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 11, no. 5, pp. 257–258, 1991. View at Google Scholar
  38. Professional Committee of Activating Blood Circulation in Chinese Association of the Integration of Traditional and Western Medicine, “Criteria for diagnosis of blood stasis syndrome,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 7, no. 3, p. 129, 1987. View at Google Scholar
  39. C. G. Fu, Z. Y. Gao, P. L. Wang et al., “Study on the diagnostic criteria for coronary heart disease patients of blood stasis syndrome,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 32, no. 9, pp. 1285–1286, 2012. View at Google Scholar
  40. Chinese Society of Cardiology, “Guildline on diagnosis and treatment of unstable angina pectoris and non-ST elecated myocardial infarcion,” Chinese Journal of Cardiology, vol. 35, no. 4, pp. 295–304, 2007. View at Google Scholar
  41. Y. Y. Zheng, Chinese Herbal Medicine Clinical Research Guilding Principles(for Trial Implementation), Chinese Medicine and Technology Publishing House, 2002.
  42. K. J. Chen, Study on Activating Blood Circulation and Cllinical Application, Peking Union Medical College Press, 1993.
  43. Y. Gong, X. Wang, J. Liu et al., “NSPc1, a mainly nuclear localized protein of novel PcG family members, has a transcription repression activity related to its PKC phosphorylation site at S183,” FEBS Letters, vol. 579, no. 1, pp. 115–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. M. C. Tataru, H. Schulte, E. A. Von, J. Heinrich, G. Assmann, and E. Koehler, “Plasma fibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction,” Coronary Artery Disease, vol. 12, no. 3, pp. 157–165, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Naito, “Effects of fibrinogen, fibrin and their degradation products on the behavior of vascular smooth muscle cells,” Nippon Ronen Igakkai Zasshi, vol. 37, no. 6, pp. 458–463, 2000. View at Google Scholar
  46. H. L. Ma, X. Lu, H. J. Yang et al., “Fibrinogen is the one of risk factors of coronary heart disease,” Chinese Journal of Thrombosis and Hemostasis, vol. 14, no. 1, pp. 8–11, 2008. View at Google Scholar
  47. H. Xu, D. Qu, F. Zheng, D. Z. Shi, and K. J. Chen, “Clinical manifestations of “Blood-stasis and Toxin” in patients with stable coronary heart disease,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 30, no. 2, pp. 125–129, 2010. View at Google Scholar
  48. Y. Feng, H. Xu, D. Qu, F. Zheng, D. Z. Shi, and K. J. Chen, “Study on the tongue manifestations for the blood-stasis and toxin syndrome in the stable patients of coronary heart disease,” Chinese Journal of Integrative Medicine, vol. 17, no. 5, pp. 333–338, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Chen, The clinical research on differentiation standard for toxin-stasis syndrome of ACS in Chinese medicine [Doctoral dissertation], China Academy of Chinese Medical Sciences, 2009.
  50. http://www.uniprot.org/uniprot/Q14624.
  51. N. H. Choi-Miura, K. Takahashi, M. Yoda et al., “The novel acute phase protein, IHRP, inhibits actin polymerization and phagocytosis of polymorphonuclear cells,” Inflammation Research, vol. 49, no. 6, pp. 305–310, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Fujita, Y. Ezura, M. Emi et al., “Hypercholesterolemia associated with splice-junction variation of inter-α-trypsin inhibitor heavy chain 4 (ITIH4) gene,” Journal of Human Genetics, vol. 49, no. 1, pp. 24–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Piñeiro, M. Andrés, M. Iturralde et al., “ITIH4 (inter-alpha-trypsin inhibitor heavy chain 4) is a new acute-phase protein isolated from cattle during experimental infection,” Infection and Immunity, vol. 72, no. 7, pp. 3777–3782, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. R. S. Kashyap, A. R. Nayak, P. S. Deshpande et al., “Inter-α-trypsin inhibitor heavy chain 4 is a novel marker of acute ischemic stroke,” Clinica Chimica Acta, vol. 402, no. 1-2, pp. 160–163, 2009. View at Publisher · View at Google Scholar · View at Scopus